Fee-for-service hit discovery is backwards. Small molecule biotechs should not have to pay when discovery vendors fail to discover potent, developable hits.

OpenBench offers a simple solution. We bear the cost of virtual screening, synthesis, and experimental confirmation, so that our partners only pay for validated hits. This results-driven paradigm fosters partnership and operational efficiency.

We construct hit criteria jointly with partners to ensure outcomes motivate further hit-to-lead pursuit. Once a deal is in place, our partners receive compounds in their labs in 2 months with validation soon to follow.

OpenBench’s technology uniquely enables this results-driven paradigm. We manage scientific risk by picking hits from massive virtual libraries >100x more efficiently than conventional methods. Screening and judiciously filtering billion-compound libraries ensures novelty and developability of hits—traits conventional solutions cannot promise.